Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.
Opinion|Podcasts|March 28, 2025
Advancing Parkinson’s Disease Care While Maintaining Focus on Dyskinesia
Listen
0:00 / 0:00
Panelists discuss how recent advancements in Parkinson’s disease treatments and a patient-centered approach to care are essential in managing dyskinesia while improving overall symptom control.
Advertisement
Summary for Physicians: "Advancing Parkinson’s Disease Care While Maintaining Focus on Dyskinesia"
This MEDCast presentation discusses the evolving therapeutic landscape in Parkinson’s disease (PD) care, particularly in managing dyskinesia.
Key Discussion Points:
- Development of Dyskinesia in PD:
Both Dr. Kremens and Dr. Hauser explore the factors that contribute to the onset of dyskinesia in PD patients, particularly after long-term use of levodopa-based therapies. - Recent Approvals in PD Treatment:
New treatments, including continuous subcutaneous foscarbidopa/foslevodopa (2024), apomorphine (2025), and levodopa/carbidopa extended-release (2024), have been approved. These medications are expected to improve symptom control and may influence the development of dyskinesia. - Impact on Dyskinesia Development:
The panel discusses how these recent approvals are expected to affect dyskinesia rates, with a focus on the importance of timely management and patient-provider discussions about dyskinesia. - Treatment Options for Dyskinesia:
The management of dyskinesia includes pharmacological options such as amantadine delayed-release/extended-release capsules, with Dr. Hauser offering insights based on clinical experience. Adjustments in treatment strategies are necessary based on the severity and type of dyskinesia a patient experiences. - Adjunct Treatments and Surgical Options:
The panel explores when to consider adjunct treatments or refer patients for surgery, highlighting the importance of individualizing care as dyskinesia progresses. - Clinical Recommendations:
Drs. Kremens and Hauser emphasize the importance of discussing dyskinesia with patients in 2025 and ensuring timely interventions. They offer advice on adjusting treatment plans for various manifestations of dyskinesia.
In conclusion, the session stresses the importance of staying updated on new PD treatments and maintaining a patient-centered approach to managing dyskinesia effectively.
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.
Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.
The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]
Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.
Shadi Yaghi, MD, FAHA, Chair of Neurology at Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center, discusses a new calculator that predicts stroke risk within 30 days of a procedure.
The clinical professor of neurology and pediatrics at The Ohio State University Wexner Medical Center discussed payer step therapy, earlier preventive treatment, and questions the updated guideline leaves open.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
The Expanding Role of Blood-Based Biomarkers in MS Care
2
Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials
3
Insights on the Updated 2026 AHA/ASA Stroke Rehabilitation Guidelines
4
Joanna Wardlaw, MD, on Biomarkers, Repurposed Drugs, and the Future of Small Vessel Disease Treatment
5